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Indroduction
Melatonin, the "light of night", is a very important hor-
mone for the function of the human organism. Its secre-
tion increases in early childhood. In adolescence there is a
decrease of the hormone concentration. The levels con-
tinue to decline gradually during middle age. In an older
population the levels of melatonin in the serum are very
low. Among many other functions, melatonin is involved
in human sexual maturation and then declines, affecting
menses and osteogenesis.
Methods and materials
The development of menarche could be explored for evi-
dence of hormesis. Hormesis is defined as the response of
cells or organisms to an exogenous substance (e.g. a drug
or toxin) or an intrinsic factor (e.g. a hormone) in which
the factor induces stimulatory or beneficial effects at low
doses and inhibitory or adverse effects at high doses
[bimodal dose-response] or vice versa.
Results
When menarche is at about 10 years, this is the age at
which AIS appears, and the circulating melatonin levels
are about 120 pg/ml - positive hormesis for menses, figure
1. If there is a circulating melatonin defect, then a delay of
menarche compared with the normal peers is expected,
and subsequently, the female is susceptible to scoliosis. In
this way, melatonin could be certainly involved in the
pathogenesis of Scoliosis [1]. Around the age of 45 years
when the circulating melatonin levels are about 20 pg/ml
- negative hormesis for menses - (figure 1), menopause
begins. As a result of the problems of osteoporosis, frac-
tures then start [2-5].
Discussion
The bone-protecting effect of melatonin is well docu-
mented in ovariectomized rats which can depend in part
on the free radical scavenging properties of melatonin.
Additionally, melatonin may impair development of oste-
openia associated with senescence by improving non-
rapid eye movement sleep and restoring GH secretion.
Whether modulation of blood levels of melatonin can be
used as a novel mode of therapy for scoliosis and aug-
menting bone mass in diseases deserves to be studied [3].
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